Search
Novartis AG
NVSAdd to Watchlist
159.990USD
-3.100-1.90%
Close 09-04 16:00（ET）
304.10BMarket Cap
22.77P/E TTM
Revenue Breakdown
Currency: USDUpdated: Tue, Sep 1
Currency: USDUpdated: Tue, Sep 1
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
By BusinessUSD
Name
Revenue
Proportion
Rest of portfolio
2.63B
18.23%
Immunology - Cosentyx
1.82B
12.66%
Oncology -Kisqali
1.70B
11.76%
Neuroscience - Kesimpta
1.42B
9.88%
Cardiovascular, Renal and Metabolism - Entresto
1.18B
8.20%
Other
5.66B
39.26%
By RegionUSD
Name
Revenue
Proportion
US
5.95B
41.32%
Europe
4.44B
30.82%
Asia / Africa / Australasia
3.02B
20.95%
Canada and Latin America
995.00M
6.91%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Rest of portfolio
2.63B
18.23%
Immunology - Cosentyx
1.82B
12.66%
Oncology -Kisqali
1.70B
11.76%
Neuroscience - Kesimpta
1.42B
9.88%
Cardiovascular, Renal and Metabolism - Entresto
1.18B
8.20%
Other
5.66B
39.26%